IGC Stock Financial Analysis - IGC Pharma, Inc. (NYSEAM) Stock

Overview

IGC Pharma, Inc., based in the United States, operates primarily within the biotechnology sector, focusing on the development and commercialization of cannabinoid-based therapies for medical conditions that currently have limited treatment options. The company is actively engaged in pioneering research projects centered around Alzheimer’s disease and other neurological conditions. One of its notable ventures involves the formulation of IGC-AD1 (Hyblonol), which is in the clinical trial phase aimed at alleviating symptoms of Alzheimer’s. Additionally, IGC Pharma’s portfolio extends into the development of novel therapeutic agents designed to treat severe pain and seizures, supporting its position as a prominent innovator in cannabinoid pharmacology in the healthcare industry.

Quality, Value, Momentum Scores

This card shows the Quality, Value, and Momentum scores for the company

Quality

The QualityScore is a proprietary scoring model that identifies high quality companies, based on cash generating efficiencies.

Value

Proprietary scoring model that ranks companies based on their relative valuation. Scores range from 0 to 100, with 100 being the most undervalued.

Momentum

Proprietary scoring model that ranks companies on their six-month momentum.

Fund Sentiment

The Fund Sentiment (fka Ownership) score is a proprietary quantitative model that ranks companies based on levels of ownership accumulation.

QVM

The QVM Score is a proprietary scoring model that combines Quality, Value, and Momentum into a single metric that ranks companies from 0 to 100.

Income Statement: Revenue, Operating Income, Net Income

The revenue for IGC Pharma, Inc. as of June 30, 2025 is 1.33 MM.
The operating income for IGC Pharma, Inc. as of June 30, 2025 is -6.98 MM.
The net income for IGC Pharma, Inc. as of June 30, 2025 is -6.34 MM.

Period End (TTM)	Revenue (MM)	Operating Income (MM)	Net Income (MM)
2025-06-30	1.33	-6.98	-6.34
2025-03-31	1.27	-7.45	-7.12
2024-12-31	1.24	-8.90	-8.81
2024-09-30	1.18	-9.32	-12.57
2024-06-30	1.06	-10.05	-13.30
2024-03-31	1.34	-9.80	-13.00
2023-12-31	1.22	-11.03	-14.14
2023-09-30	1.34	-10.95	-10.80
2023-06-30	1.25	-10.89	-10.80
2023-03-31	0.91	-11.57	-11.51
2022-12-31	0.87	-13.09	-13.98
2022-09-30	0.68	-13.30	-14.11
2022-06-30	0.53	-15.20	-16.01
2022-03-31	0.40	-14.60	-15.02
2021-12-31	0.36	-11.72	-11.46
2021-09-30	0.32	-11.66	-11.40
2021-06-30	0.39	-8.99	-8.72
2021-03-31	0.90	-8.72	-8.81
2020-12-31	0.85	-8.38	-9.02
2020-09-30	1.31	-7.73	-8.30

Income Statement: EPS

Period End (TTM)	Earnings Per Share Basic	Earnings Per Share Diluted
2025-06-30
2025-03-31	-0.09
2024-12-31	-0.12	-0.12
2024-09-30	-0.18	-0.18
2024-06-30	-0.21	-0.21
2024-03-31	-0.22
2023-12-31	-0.25	-0.25
2023-09-30	-0.20	-0.20
2023-06-30	-0.20	-0.20
2023-03-31	-0.22
2022-12-31	-0.27	-0.27
2022-09-30	-0.27	-0.27
2022-06-30	-0.31	-0.31
2022-03-31	-0.30
2021-12-31	-0.24	-0.24
2021-09-30	-0.25	-0.25
2021-06-30	-0.20	-0.20
2021-03-31	-0.21
2020-12-31	-0.22	-0.22
2020-09-30	-0.21	-0.21

Cash Flow: Operations, Investing, Financing

The cash from operating activities for IGC Pharma, Inc. as of June 30, 2025 is -4.45 MM.
The cash from investing activities for IGC Pharma, Inc. as of June 30, 2025 is 0.27 MM.
The cash from financing activities for IGC Pharma, Inc. as of June 30, 2025 is 2.79 MM.

Period End (TTM)	Cash From Operating Activities (MM)	Cash From Investing Activities (MM)	Cash From Financing Activities (MM)
2025-06-30	-4.45	0.27	2.79
2025-03-31	-4.79	-0.44	4.45
2024-12-31	-4.59	-0.62	4.31
2024-09-30	-4.86	-0.58	3.97
2024-06-30	-5.48	-0.44	6.03
2024-03-31	-5.20	-0.32	3.52
2023-12-31	-6.19	-0.24	2.86
2023-09-30	-6.25	-0.19	2.86
2023-06-30	-6.32	-0.08	0.10
2023-03-31	-7.05	-0.23	0.10
2022-12-31	-6.42	-0.55	0.10
2022-09-30	-7.19	-0.58	0.10
2022-06-30	-7.81	-0.81	3.42
2022-03-31	-7.46	-0.74	4.14
2021-12-31	-9.08	1.74	18.30
2021-09-30	-8.50	3.44	18.30
2021-06-30	-8.66	4.43	14.83
2021-03-31	-10.80	3.39	14.69
2020-12-31	-10.29	0.72	0.45
2020-09-30	-10.68	-2.63	0.45

Valuation Metrics : PE, PriceToBook, PriceToTBV

The p/e for IGC Pharma, Inc. as of June 30, 2025 is -3.48.
The p/book for IGC Pharma, Inc. as of June 30, 2025 is 3.91.
The p/tbv for IGC Pharma, Inc. as of June 30, 2025 is 5.53.

P/Book: The current closing price divided by the book value per share.

P/TBV: The current price divided by the tangible book value per share.

Period End (TTM)	p/e	P/Book	P/TBV
2025-06-30	-3.48	3.91	5.53
2025-03-31		3.74	5.34
2024-12-31		3.72	4.92
2024-09-30	-2.01	3.40	4.35
2024-06-30	-2.26	3.54	4.07
2024-03-31	-1.90	2.97	3.41
2023-12-31	-1.66	1.27	1.39
2023-09-30	-1.79	1.47	1.61
2023-06-30	-1.21	0.92	0.98
2023-03-31	-1.26	0.96
2022-12-31		0.84	0.88
2022-09-30		1.05	1.10
2022-06-30	-1.90	1.19	1.24
2022-03-31	-4.21	1.64	1.66
2021-12-31	-4.35	1.59	1.61
2021-09-30	-8.72	2.40	2.43
2021-06-30
2021-03-31	-4.08	1.10	1.11
2020-12-31	-3.44	1.45	1.47
2020-09-30	-3.74	1.32	1.33

Valuation Metrics : EBitToEv, EBit3YrAvgToEv

The ebit/ev for IGC Pharma, Inc. as of June 30, 2025 is -0.29.
The ebit (3y)/ev for IGC Pharma, Inc. as of June 30, 2025 is -0.42.

Period End (TTM)	EBIT/EV	EBIT (3y)/EV
2025-06-30	-0.29	-0.42
2025-03-31	-0.38	-0.50
2024-12-31	-0.48	-0.52
2024-09-30	-0.53	-0.51
2024-06-30	-0.46	-0.44
2024-03-31	-0.55	-0.52
2023-12-31	-0.72	-0.81
2023-09-30	-0.61	-0.67
2023-06-30	-1.15	-1.07
2023-03-31	-1.09	-0.98
2022-12-31	-1.36	-1.08
2022-09-30	-1.05	-0.78
2022-06-30	-0.83	-0.58
2022-03-31	-0.31	-0.25
2021-12-31	-0.32	-0.25
2021-09-30	-0.14	-0.12
2021-06-30
2021-03-31	-0.40	-0.30
2020-12-31	-0.29	-0.19
2020-09-30	-0.27	-0.18

Management Effectiveness

The roa for IGC Pharma, Inc. as of June 30, 2025 is -0.67.
The roe for IGC Pharma, Inc. as of June 30, 2025 is -0.90.
The roic for IGC Pharma, Inc. as of June 30, 2025 is -1.08.
The croic for IGC Pharma, Inc. as of June 30, 2025 is -0.12.
The ocroic for IGC Pharma, Inc. as of June 30, 2025 is -0.73.

Period End (TTM)	ROA	ROE	ROIC	CROIC	OCROIC
2025-06-30	-0.67	-0.90	-1.08	-0.12	-0.73
2025-03-31	-0.78	-0.97	-1.35	-0.14	-0.70
2024-12-31	-1.12	-1.39	-1.64	-0.19	-0.63
2024-09-30	-0.81	-0.94	-1.62	0.01	-0.67
2024-06-30	-0.82	-0.95	-1.50	-0.38	-0.66
2024-03-31	-0.70	-0.77	-1.50	-0.38	-0.66
2023-12-31	-0.49	-0.54	-0.74	-0.25	-0.43
2023-09-30	-0.45	-0.49	-0.79	-0.46	-0.46
2023-06-30	-0.58	-0.63	-0.79	-0.46	-0.46
2023-03-31	-0.52	-0.59	-0.75	-0.47	-0.46
2022-12-31	-0.42	-0.45	-0.68	-0.38	-0.35
2022-09-30	-0.47	-0.51	-0.68	-0.38	-0.35
2022-06-30	-0.44	-0.47	-0.71	-0.23	-0.35
2022-03-31	-0.32	-0.35	-0.61	-0.17	-0.30
2021-12-31	-0.47	-0.53	-0.38	0.36	-0.27
2021-09-30	-0.43	-0.37	-0.36	0.41	-0.27
2021-06-30	-0.31	-0.35	-0.27	0.33	-0.27
2021-03-31	-0.30	-0.33	-0.26	0.21	-0.32
2020-12-31	-0.29	-0.30	-0.40	-0.40	-0.45
2020-09-30	-0.25	-0.27	-0.34	-0.52	-0.43

Gross Margins

The gross margin for IGC Pharma, Inc. as of June 30, 2025 is 0.49.
The net margin for IGC Pharma, Inc. as of June 30, 2025 is -5.60.
The operating margin for IGC Pharma, Inc. as of June 30, 2025 is -5.86.

Gross Margin: The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.

Net Margin: The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.

Operating Margin: The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.

Period End (TTM)	Gross Margin	Net Margin	Operating Margin
2025-06-30	0.49	-5.60	-5.86
2025-03-31	0.51	-7.13	-7.20
2024-12-31	0.56	-10.62	-7.88
2024-09-30	0.60	-12.53	-9.46
2024-06-30	0.51	-11.63	-9.07
2024-03-31	0.51	-11.63	-9.07
2023-12-31	0.44	-8.05	-8.15
2023-09-30	0.44	-8.61	-8.68
2023-06-30	0.52	-8.61	-8.68
2023-03-31	0.52	-12.63	-12.70
2022-12-31	0.60	-20.81	-13.03
2022-09-30	0.58	-20.81	-13.03
2022-06-30	0.49	-30.10	-20.04
2022-03-31	0.43	-37.82	-36.10
2021-12-31	0.33	-32.20	-31.63
2021-09-30	0.24	-35.42	-33.37
2021-06-30	0.24	-22.29	-21.62
2021-03-31	0.13	-9.81	-9.12
2020-12-31	0.12	-10.66	-9.90
2020-09-30	0.09	-6.33	-5.89